Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
In addition to sample collection for Center for Cancer Genomics (CCG) collaborations, CCG's Pathology Team is integrated into the research biopsy collection process for all Dana-Farber research biopsies performed at Brigham and Women's Hospital Cross-Sectional
Interventional Radiology (BWH CSIR). This initiative is called the Dana-Farber CSIR Biopsy Collection Initiative, or DCBC.
DCBC arose from the desire to unify the collection of all research biopsy samples from BWH CSIR and create a consistent, organized, and responsive process for procuring samples directly from radiology staff on behalf of all Dana-Farber research protocols,
investigators, and disease centers. Under this initiative, CCG's trained pathology technicians communicate the research study needs to CSIR and allocate the tissue to protocols according to a specified priority list. In doing so, the pathology technicians
standardize the procurement of research tissue samples from CSIR.
If you have any questions about the Dana-Farber CSIR Biopsy Collections, please email DFCI_Bx_CollectionsOPS@dfci.harvard.edu.
Dana-Farber researchers can access DCBC resources at https://partnershealthcare.sharepoint.com/sites/dfcicto/SitePages/BWH-CSIR.aspx.
CCG Associate Director: Aaron ThornerDCBC Biopsy Collections: Karla HelvieBioinformatics: Tony Anselmo
For general questions:617-582-7253 email@example.com